These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28984058)

  • 1. Multivariate analysis of risk factors for cisplatin-induced nephrotoxicity in gynecological cancer.
    Yamamoto Y; Watanabe K; Matsushita H; Tsukiyama I; Matsuura K; Wakatsuki A
    J Obstet Gynaecol Res; 2017 Dec; 43(12):1880-1886. PubMed ID: 28984058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
    Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer.
    Miyoshi T; Misumi N; Hiraike M; Mihara Y; Nishino T; Tsuruta M; Kawamata Y; Hiraki Y; Kozono A; Ichiki M
    Biol Pharm Bull; 2016; 39(12):2009-2014. PubMed ID: 27904042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
    Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
    Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
    Saito Y; Kobayashi M; Yamada T; Kasashi K; Honma R; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Iseki K
    Support Care Cancer; 2017 Feb; 25(2):481-487. PubMed ID: 27699503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer.
    Kimura T; Ozawa T; Hanai N; Hirakawa H; Suzuki H; Hosoi H; Hasegawa Y
    J Otolaryngol Head Neck Surg; 2018 Feb; 47(1):10. PubMed ID: 29394952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.
    Kidera Y; Kawakami H; Sakiyama T; Okamoto K; Tanaka K; Takeda M; Kaneda H; Nishina S; Tsurutani J; Fujiwara K; Nomura M; Yamazoe Y; Chiba Y; Nishida S; Tamura T; Nakagawa K
    PLoS One; 2014; 9(7):e101902. PubMed ID: 25020203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
    Merouani A; Davidson SA; Schrier RW
    Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between magnesium pre-loading and cisplatin-induced nephrotoxicity in 5-fluorouracil/cisplatin combination therapy for esophageal cancer.
    Sugisaki T; Aoyama T; Kawakami K; Yokokawa T; Kobayashi K; Suzuki W; Ogura M; Ichimura T; Chin K; Yamaguchi K; Hanaoka S; Hayashi H; Yamaguchi M
    Pharmazie; 2022 Feb; 77(2):85-88. PubMed ID: 35209969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity.
    Sendur MA; Aksoy S; Yaman S; Arik Z; Tugba Kos F; Akinci MB; Civelek B; Yildirim Ozdemir N; Uncu D; Zengin N
    J BUON; 2013; 18(1):274-80. PubMed ID: 23613416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis.
    Yamaguchi T; Uozu S; Isogai S; Hayashi M; Goto Y; Nakanishi T; Imaizumi K
    Support Care Cancer; 2017 Apr; 25(4):1215-1220. PubMed ID: 27966021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review for prevention of cisplatin-induced nephrotoxicity using different hydration protocols and meta-analysis for magnesium hydrate supplementation.
    Li J; Wu Y; Chen C; Zhang W; Yue L; Liu T
    Clin Exp Nephrol; 2024 Jan; 28(1):1-12. PubMed ID: 37530867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors.
    Sato K; Watanabe S; Ohtsubo A; Shoji S; Ishikawa D; Tanaka T; Nozaki K; Kondo R; Okajima M; Miura S; Tanaka J; Sakagami T; Koya T; Kagamu H; Yoshizawa H; Narita I
    BMC Cancer; 2016 Mar; 16():222. PubMed ID: 26979596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
    Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
    BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney-protective Effect of Magnesium Supplementation in Cisplatin-containing Chemotherapy for Pediatric Cancer: A Retrospective Study.
    Matsui M; Saito Y; Yamaoka S; Yokokawa Y; Morikawa Y; Makimoto A; Yuza Y
    J Pediatr Hematol Oncol; 2018 Jul; 40(5):379-381. PubMed ID: 29683958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin.
    Yamamoto Y; Watanabe K; Tsukiyama I; Matsushita H; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2015 Apr; 35(4):2199-204. PubMed ID: 25862878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients.
    Saito Y; Kobayashi M; Tamaki S; Nakamura K; Hirate D; Takahashi K; Takekuma Y; Sakakibara-Konishi J; Shimizu Y; Kinoshita I; Sugawara M
    Sci Rep; 2023 Oct; 13(1):17126. PubMed ID: 37816823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Utility of the Predictive Score for Cisplatin-Induced Nephrotoxicity in Patients with Chemotherapy for Lung Cancer].
    Sakurai T; Takada K; Kojima E; Yamashita Y; Akazawa N; Ito S; Watanabe S
    Gan To Kagaku Ryoho; 2019 Dec; 46(12):1849-1853. PubMed ID: 31879402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.
    Crona DJ; Faso A; Nishijima TF; McGraw KA; Galsky MD; Milowsky MI
    Oncologist; 2017 May; 22(5):609-619. PubMed ID: 28438887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
    Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML
    J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.